News

Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that David P. White, M.D., a world-renowned leader in sleep disorders has been appointed Senior Vice President of Medical Affairs.

CAMBRIDGE, Mass. July 6, 2021 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Company’s management team will participate in the Ladenburg...

CAMBRIDGE, Mass. May 25, 2021 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Company’s management team will participate in the Jefferies Virtual Healthcare Conference, held June 1-4, 2021. Apnimed’s presentation is scheduled for Tuesday, June 1st at 4:30pm ET. Management will be available June 1st throughout the day for virtual one-on-one meetings.

CAMBRIDGE, Mass. May 17, 2021 – Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for sleep apnea and related disorders, announced today that researchers from Istituto Auxologico Italiano and Brigham and Women’s Hospital presented data on the company’s investigational treatment for obstructive sleep apnea, AD128, at the American Thoracic Society (ATS) Meeting, taking place from May 14-19, 2021.

Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Company’s management team will participate in the 20th Annual Needham Virtual Healthcare Conference, held April 12-15, 2021. Apnimed’s presentation is scheduled for Thursday, April 15th at 3:45 pm ET.

Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for sleep apnea and related disorders, announced today that it has raised $25 million in a Series B financing led by existing investor, Morningside Ventures, and joined by new investors, Seligman Investments and Tao Capital Partners. The proceeds will support Apnimed’s ongoing development and commercialization plans. The company is advancing its lead program, AD109, an oral disease-modifying therapeutic for the treatment of Obstructive Sleep Apnea (OSA), which is currently in late-stage Phase 2 clinical trials.

Apnimed will participate in the Oppenheimer 31st Annual Healthcare Conference, held virtually March 16-18, 2021. Apnimed’s presentation is scheduled for Wednesday, March 17th from 3:50 – 4:20 pm (ET).

– Dr. White joins Apnimed as Distinguished Scientist and Chair of the company’s Scientific Advisory Board – – Additionally, Luigi Taranto Montemurro, M.D., promoted to Chief Scientific Officer – CAMBRIDGE, Mass. March 04, 2021 – Apnimed, a clinical-stage company...

Apnimed, a clinical-stagepharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating AD109 as a treatment for mild to moderate OSA. If successful, AD109 could offer an entirely new approach to treating OSA with a once-daily, oral medication that addresses the underlying biology of the disease.

CAMBRIDGE, Mass. November 30, 2020 – Apnimed, a clinical-stage pharmaceutical company focused on advancing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that Dr. Luigi Taranto Montemurro, the company’s Medical Director will present at the World Sleep Conference, held virtually December 3-5, 2020. Dr. Taranto Montemurro’s presentation discussing pharmacotherapy for OSA is scheduled for Friday, December 4th from 6:00 – 6:30 PM EST.